Gastric Cancer Gene-Edited Cell Lines for Drug Discovery

Gastric cancer (GC) is the fifth most common cancer and the fourth leading cause of cancer death worldwide, with over 1.1 million new cases and approximately 770,000 deaths annually (WHO GLOBOCAN 2022). The highest incidence rates are in Eastern Asia, Eastern Europe, and South America. Major risk factors include Helicobacter pylori infection (classified as a Group 1 carcinogen by IARC), smoking, high salt intake, and genetic predisposition (e.g., CDH1 mutations in hereditary diffuse gastric cancer). The 5-year survival rate for localized GC is about 70%, but drops to less than 6% for metastatic disease (NCI SEER data). This stark disparity underscores the urgent need for improved therapeutic strategies and predictive biomarkers.

Gastric cancer is highly heterogeneous, classified by histology (intestinal, diffuse, mixed) and molecular subtypes (TCGA: EBV+, MSI, genomically stable, chromosomal instability). This diversity makes it an ideal model for studying tumor evolution, clonal selection, and therapy resistance. Public datasets from TCGA, COSMIC, and DepMap provide extensive genomic, transcriptomic, and dependency data, enabling hypothesis-driven research. Key open questions include the role of the tumor microenvironment, mechanisms of immune evasion, and identification of synthetic lethal vulnerabilities.

• • Gastric carcinogenesis involves a stepwise accumulation of genetic and epigenetic alterations. Key pathways include:
• • Chronic inflammation and metaplasia: H. pylori infection leads to chronic gastritis, atrophic gastritis, intestinal metaplasia, and dysplasia.
• • Genomic instability: Microsatellite instability (MSI) due to MLH1 silencing or mismatch repair defects; chromosomal instability (CIN) leading to aneuploidy.
• • Epigenetic silencing: Promoter hypermethylation of tumor suppressor genes (e.g., CDH1, MLH1, p16).
• • Oncogenic activation: Mutations in KRAS, PIK3CA, and amplification of ERBB2 (HER2), MET, and FGFR2.

Data from TCGA (Nature 2014) and COSMIC (v99).

• • Key signaling networks in gastric cancer include:
• • Wnt/β-catenin pathway: Mutations in CTNNB1 or APC lead to nuclear β-catenin accumulation and transcription of pro-proliferative genes (MYC, CCND1).
• • MAPK/ERK pathway: KRAS and BRAF mutations drive uncontrolled cell proliferation.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations and PTEN loss activate survival and growth signals.
• • HGF/MET pathway: MET amplification promotes invasion and metastasis.
• • TGF-β pathway: Loss of TGFBR2 or SMAD4 leads to escape from growth inhibition.

Common gastric cancer cell lines and their key mutations:

Organoid models derived from patient tumors retain the genetic and phenotypic heterogeneity of the original tumor, making them valuable for drug screening and personalized medicine. However, they are more complex to culture and less amenable to high-throughput genetic manipulation than cell lines.

• • In vivo models for gastric cancer include:
• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice; retain tumor heterogeneity and drug response profiles.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Tp53 and Cdh1 in the stomach epithelium leads to invasive diffuse-type GC.
• • Carcinogen-induced models: N-methyl-N-nitrosourea (MNU) in drinking water induces gastric adenocarcinomas in rodents.
• • Syngeneic models: Cell lines (e.g., YTN16) implanted into immunocompetent mice for immunotherapy studies.

• • CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. These models are essential for studying the functional impact of specific mutations in a controlled background. Examples include:
• • TP53 knockout lines: AGS TP53-/- and MKN45 TP53-/- models to study loss of tumor suppressor function.
• • KRAS G12D knock-in lines: Introduction of the activating mutation into wild-type backgrounds to model oncogenic signaling.
• • CDH1 knockout lines: To investigate the role of E-cadherin loss in invasion and metastasis.
• • Reporter lines: e.g., GFP-tagged TP53 or luciferase reporters for drug screening.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house CRISPR optimization and validation. These models are typically validated by Sanger sequencing, western blot, and functional assays, ensuring reproducibility.

• • Gene-edited cell lines are used to validate candidate driver genes identified from sequencing studies. For example:
• • TP53 knockout in AGS cells confirms loss of cell cycle arrest and apoptosis upon DNA damage.
• • CDH1 knockout in MKN45 cells increases cell migration and invasion in transwell assays.
• • KRAS G12D knock-in in NCI-N87 cells enhances MAPK signaling and confers resistance to EGFR inhibitors.

• • Isogenic pairs (wild-type vs. mutant) are powerful tools for drug screening. Examples:
• • HER2-amplified vs. isogenic HER2-low lines to test trastuzumab sensitivity.
• • KRAS G12D knock-in lines to screen for KRAS G12D-specific inhibitors (e.g., MRTX1133).
• • TP53 knockout lines to identify synthetic lethal partners (e.g., WEE1 inhibitors).
• • Resistance modeling: chronic exposure of isogenic lines to drugs (e.g., 5-FU, cisplatin) to identify acquired resistance mechanisms.

• • CRISPR-based screens in gastric cancer cell lines can identify genes whose loss sensitizes cells to therapy. For example:
• • Genome-wide knockout screens in AGS cells identified ARID1A as a synthetic lethal partner with EZH2 inhibitors.
• • Focused screens targeting DNA repair genes in TP53-null lines revealed PARP inhibitor sensitivity.
• • CRISPR activation screens can identify genes that confer resistance to immune checkpoint inhibitors.